Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 2/20 | 0.42 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.42 |
| ▸ | CPA1 | P15085 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26088512 | 0.89 | GRIK1 (0.47) | GRIK1GRIK2CPA1CA1CA2 | |
| SCHEMBL7202052 | 0.86 | GRIK1 (0.39) | GRIK1GRIK2CPA1CA1CA2 | |
| SCHEMBL174976 | 0.84 | GRIK1 (0.50) | GRIK1GRIK2CPA1CA1CA2 | |
| SCHEMBL28012569 | 0.83 | GRIK1 (0.42) | GRIK1GRIK2CPA1CA1CA2 | |
| SCHEMBL22306014 | 0.81 | CA1 (0.45) | GRIK1GRIK2CPA1CA1CA2 | |
| SCHEMBL17343614 | 0.81 | CA1 (0.45) | GRIK1GRIK2CPA1CA1CA2 | |
| SCHEMBL8031351 | 0.80 | GRIK1 (0.53) | GRIK1GRIK2CPA1CA2TSHR | |
| SCHEMBL10898377 | 0.79 | GRIK1 (0.40) | GRIK1GRIK2CPA1CA1CA2 | |
| SCHEMBL474901 | 0.78 | CA2 (0.42) | CA1CA2TSHR | |
| SCHEMBL28191059 | 0.78 | CA2 (0.62) | GRIK1GRIK2CA1CA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365174-B2 | Azalide and azalactam derivatives and method for producing the same | MEIJI SEIKA KAISHA, LTD. (JP) | 2008-04-29 | — | — | US | disclosed |
| US-20070042974-A1 | Nozel azalide and azalactam derivatives and method for producing the same | MEIJI SEIKA KAISHA, LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1661904-A1 | NOVEL AZALIDE AND AZALACTAM DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE SAME | MEIJI SEIKA KAISHA LTD. (JP) | 2006-05-31 | — | — | EP | disclosed |
| US-5036152-A | Antiinflammatory | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1991-07-30 | — | — | US | disclosed |
| US-4888328-A | Alkoxycarbonylalkylphospholipids and alkylaminocarbonylalkylphospholipids | HOESCHST-ROUSSEL INCORPORATED (US) | 1989-12-19 | — | — | US | disclosed |
| EP-0332129-A2 | Alkoxy- and alkylamino-carbonylalkylphospholipids, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1989-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070042974-A1 | Nozel azalide and azalactam derivatives and method for producing the same | BCL6, NR4A1, NR4A2 | GRIK1 993/4885GRIK2 918/4885CPA1 3605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.